The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months.

PRIMA system led to clinically meaningful improvement in visual acuity from baseline in 26 of 32 participants with 12 months of follow-up.

Gerhardt Attard, MD, PhD, from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP vs placebo and AAP in mCSPC with HRR gene ...

Johnson & Johnson stopped selling its talc-based baby powder in the US and Canada in 2020. In 2023, it switched to a cornstarch formula. The company maintains its baby powder is safe. Its consumer ...